TY - JOUR
T1 - Management of lymph NodePositive prostate cancer
T2 - The role of surgery and radiation therapy
AU - Mitin, Timur
AU - Blute, Michael
AU - Lee, Richard
AU - Efstathiou, Jason
PY - 2013
Y1 - 2013
N2 - There is no clear consensus on how to manage a subset of patients with prostate cancer (PCa) who present with involved lymph nodes (LN+). Although outcomes for these patients are uniformly worse than those for patients with localized PCa, they are better than outcomes for patients with bone metastases, with more than 60% of patients alive at 10 years after the initial diagnosis. This article reviews the existing data on outcomes for patients treated with various combinations of systemic and local therapies. Current evidence suggests both a disease-control benefit and a survival benefit to multimodality therapy, which combines systemic androgen deprivation therapy (ADT) with local therapies, such as surgery and radiation, without evidence of excessive treatment-related toxicities.
AB - There is no clear consensus on how to manage a subset of patients with prostate cancer (PCa) who present with involved lymph nodes (LN+). Although outcomes for these patients are uniformly worse than those for patients with localized PCa, they are better than outcomes for patients with bone metastases, with more than 60% of patients alive at 10 years after the initial diagnosis. This article reviews the existing data on outcomes for patients treated with various combinations of systemic and local therapies. Current evidence suggests both a disease-control benefit and a survival benefit to multimodality therapy, which combines systemic androgen deprivation therapy (ADT) with local therapies, such as surgery and radiation, without evidence of excessive treatment-related toxicities.
UR - http://www.scopus.com/inward/record.url?scp=84880309137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880309137&partnerID=8YFLogxK
M3 - Comment/debate
C2 - 23977759
AN - SCOPUS:84880309137
SN - 0890-9091
VL - 27
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
IS - 7
ER -